<?xml version="1.0" encoding="UTF-8"?>
<p>Regretfully, these two drugs also produce numerous adverse effects in patients, such as nephrotoxicity, azotemia, proteinuria, crystalluria, interstitial nephritis, acute tubular necrosis, increases in the concentrations of creatinine up to 50%, hypo- and hypercalcemia, hypo- and hyper-phosphatemia, and the formation of urogenital ulcers, among others (
 <xref rid="B46" ref-type="bibr">Deray et al., 1989</xref>; 
 <xref rid="B164" ref-type="bibr">Sauerbrei, 2016</xref>). Because of these effects, it is recommended that patients receiving foscarnet be monitored clinically to control abnormalities in metabolites and electrolytes that may result in the alterations indicated above.
</p>
